XML 44 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business (Details)
12 Months Ended
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
Aug. 13, 2021
USD ($)
Nature of Business      
Number of operating segments | segment 2    
Accumulated deficit $ (205,765,107) $ (193,214,134)  
Net loss (12,550,973) (17,688,522)  
Net cash used in operating activities (11,739,620) (11,454,426)  
Cash and cash equivalents 26,043,897 18,676,663  
Increase of cash and cash equivalents   $ 7,367,234  
Percentage change in cash and cash equivalent   39.00%  
Working capital $ 20,278,345 $ 13,386,485  
Working capital increase (decrease) as a percent 51.00%    
Contracts and grants receivable $ 138,889 $ 203,774  
FBR Sales Agreement [Member]      
Nature of Business      
Borrowing Capacity     $ 26,800,000
CiVax      
Nature of Business      
Term (in years) two years    
Subcontract revenue $ 1,500,000    
NIH      
Nature of Business      
Contracts and grants receivable $ 1,350,000    
NIAID | Contract revenue      
Nature of Business      
Term (in years) five years    
Subcontract revenue $ 700,000    
DTRA | Contract revenue      
Nature of Business      
Term (in years) three years    
Subcontract revenue $ 600,000